Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Colorcon
Merck
Boehringer Ingelheim
Harvard Business School

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OTREXUP PFS

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Otrexup Pfs

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00335140 ↗ Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma Terminated National Cancer Institute (NCI) Phase 2 2006-12-01 RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.
NCT00335140 ↗ Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma Terminated Eastern Cooperative Oncology Group Phase 2 2006-12-01 RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.
NCT00439296 ↗ ABT-751 With Chemotherapy for Relapsed Pediatric ALL Terminated Abbott Phase 1/Phase 2 2006-05-22 This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemotherapy has been found, the study will add additional patients to find out if ABT-751 (given at the maximal safe dose) when given with additional chemotherapy is an effective therapy for the treatment of children with relapsed ALL. It is expected that approximately 15-35 children and young adults will take part in this study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Otrexup Pfs

Condition Name

Condition Name for Otrexup Pfs
Intervention Trials
Acute Lymphoblastic Leukemia 3
Lymphoblastic Leukemia, Acute, Childhood 1
Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Otrexup Pfs
Intervention Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 6
Leukemia, Lymphoid 6
Leukemia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Otrexup Pfs

Trials by Country

Trials by Country for Otrexup Pfs
Location Trials
United States 68
Canada 6
Australia 5
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Otrexup Pfs
Location Trials
Minnesota 5
Florida 5
California 5
Michigan 5
Washington 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Otrexup Pfs

Clinical Trial Phase

Clinical Trial Phase for Otrexup Pfs
Clinical Trial Phase Trials
Phase 2 1
Phase 1/Phase 2 3
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Otrexup Pfs
Clinical Trial Phase Trials
Terminated 3
Completed 2
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Otrexup Pfs

Sponsor Name

Sponsor Name for Otrexup Pfs
Sponsor Trials
Therapeutic Advances in Childhood Leukemia Consortium 4
Pfizer 2
National Cancer Institute (NCI) 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Otrexup Pfs
Sponsor Trials
Other 12
Industry 3
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Baxter
Harvard Business School
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.